Systemic Therapy for Metastatic Non-Clear-Cell Renal Cell Carcinoma: Recent Progress and Future Directions

Simon Chowdhury, Marc R. Matrana, Christopher Tsang, Bradley Atkinson, Toni K. Choueiri, Nizar M. Tannir*

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    27 Citations (Scopus)

    Abstract

    Insights into the biology of clear-cell renal cell carcinoma (CCRCC) have identified multiple pathways associated with the pathogenesis and progression of this cancer. This progress has led to the development of multiple agents targeting these pathways, including the tyrosine kinase inhibitors sorafenib, sunitinib, and pazopanib, the monoclonal antibody bevacizumab, and the mTOR inhibitors temsirolimus and everolimus. With the exception of temsirolimus, phase 3 trials tested these agents in patients with clear-cell histology; therefore, their efficacy in non-CCRCC is unclear. To date, there is no established effective therapy for patients with advanced non-CCRCC. This article focuses on treatment options for metastatic non-CCRCC.

    Original languageEnglish
    Pages (from-to)853-+
    Number of pages19
    JournalHematology/Oncology Clinics of North America
    Volume25
    Issue number4
    DOIs
    Publication statusPublished - Aug 2011

    Keywords

    • Non-clear-cell renal cell carcinoma
    • Targeted therapy
    • Papillary
    • Chromophobe
    • Unclassified
    • Renal medullary carcinoma
    • Collecting duct carcinoma
    • Sarcomatoid dedifferentiation
    • ENDOTHELIAL GROWTH-FACTOR
    • TYROSINE KINASE INHIBITOR
    • COLLECTING DUCT CARCINOMA
    • FACTOR-TARGETED THERAPY
    • OF-THE-LITERATURE
    • PHASE-II TRIAL
    • MEDULLARY CARCINOMA
    • INTERFERON-ALPHA
    • ANTITUMOR-ACTIVITY
    • TRANSLOCATION CARCINOMAS

    Fingerprint

    Dive into the research topics of 'Systemic Therapy for Metastatic Non-Clear-Cell Renal Cell Carcinoma: Recent Progress and Future Directions'. Together they form a unique fingerprint.

    Cite this